Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

In the version of this article initially published, the title of the paper, now reading "Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial," appeared incorrectly as "Axicabtagene ciloleucel in l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature Medicine 2023-10, Vol.29 (10), p.2665-2665
Hauptverfasser: Houot, Roch, Bachy, Emmanuel, Cartron, Guillaume, Gros, François-Xavier, Morschhauser, Franck, Oberic, Lucie, Gastinne, Thomas, Feugier, Pierre, Duléry, Rémy, Thieblemont, Catherine, Joris, Magalie, Jardin, Fabrice, Choquet, Sylvain, Casasnovas, Olivier, Brisou, Gabriel, Cheminant, Morgane, Bay, Jacques-Olivier, Gutierrez, Francisco Llamas, Menard, Cédric, Tarte, Karin, Delfau, Marie-Hélène, Portugues, Cédric, Itti, Emmanuel, Palard-Novello, Xavier, Blanc-Durand, Paul, Al Tabaa, Yassine, Bailly, Clément, Laurent, Camille, Lemonnier, François
Format: Artikel
Sprache:eng
Schlagworte:
692/308/2779/109/1941
692/699/67/1059/2325
692/699/67/1990/291/1621/1915
Biomedical and Life Sciences
Biomedicine
Cancer Research
Human health and pathology
Infectious Diseases
Life Sciences
Lymphoma
Metabolic Diseases
Molecular Medicine
Neurosciences
Publisher
Publisher Correction
Stem cells
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the version of this article initially published, the title of the paper, now reading "Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial," appeared incorrectly as "Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial.
ISSN:1078-8956
1546-170X
1744-7933
DOI:10.1038/s41591-023-02624-w